4422-32-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(3-bromophenyl)Pyridine is used as a reactant for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 3-(3-bromophenyl)Pyridine serves as a valuable starting material for the exploration of new chemical reactions and the synthesis of novel organic compounds.
Used in OLED Manufacturing:
3-(3-bromophenyl)Pyridine is used as a reactant in the process for the synthesis of compounds such as 11H-indeno[1,2-a]quinoline derivatives. These derivatives are utilized in the manufacturing of OLED (organic light emitting devices), which are known for their high efficiency, low power consumption, and thin, flexible design.

Upstream product

• 591-18-4 1-Bromo-3-iodobenzene 
• 59020-09-6 3-(trimethylstannyl)pyridine 
• 108-36-1 1,3-dibromobenzene 
• 89878-14-8 3-Diethylboranylpyridine 
• 329214-79-1 3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1692-25-7 3-pyridylboronic acid 
• 110-86-1 pyridine 
• 585-76-2 m-bromobenzoic acid 
• 10269-01-9 3-bromobenzylamine 

Downstream Products

• 247214-57-9 3-[3'-(diethylboryl)phenyl]pyridine 
• 265644-07-3 3-[3-(tri-n-butylstannanyl)phenyl]pyridine 
• 939430-30-5 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine 
• 1197989-80-2 C₄₀H₃₅BN₂O₂ 
• 1197989-81-3 C₇₃H₄₉N₅ 
• 1197993-07-9 C₃₄H₃₁BN₂O₂ 
• 1197993-09-1 3,3'-(5'-chloro-[1,1':3',1''-terphenyl]-3,3''-diyl)dipyridine 
• 1165939-26-3 1,3-bis(3-pyridinephenyl)-5-(3-bromophenyl)benzene 
• 1219604-01-9 C₇₂H₄₈N₆ 
• 1219603-98-1 3-bromo-5-(3'-(3''-pyridylphenyl))pyridine 
• 1219604-00-8 C₅₄H₃₆N₆ 
• 1436712-28-5 C₂₁H₁₈N₂O₂S 
• 1436712-31-0 C₂₁H₁₉N₃OS 
• 1436712-25-2 C₁₉H₁₆N₂O 

Relevant academic research and scientific papers

ASK1 inhibitor, derivative, preparation method, pharmaceutical composition and application thereof

The invention discloses an ASK1 inhibitor, a derivative, a preparation method, a pharmaceutical composition and application thereof. The structure of the compound is shown as a formula I. The ASK1 inhibitor derivative relates to an isomer, a diastereoisom

Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors

Apoptosis signal-regulating kinase 1 (ASK1, MAP3K5), a member of the mitogen-activated protein kinase (MAPK) signaling pathway, is involved in cell survival, differentiation, stress response, and apoptosis. ASK1 kinase inhibition has emerged as a promisin

Nitrogen-containing organic compound, application thereof and organic light-emitting device

The invention relates to the field of organic light-emitting devices, and discloses a nitrogen-containing organic compound, application thereof and an organic light-emitting device. The nitrogen-containing organic compound has a structure as shown in a fo

Anthracene derivatives and organic light-emitting diode including the same

PURPOSE: An anthracene derivative is provided to have excellent power efficiency by low voltage operation and to provide an organic electroluminescent device with excellent luminance efficiency and a long lifetime. CONSTITUTION: An anthracene derivative is represented by chemical formula 1. An organic electroluminescent device includes an anode(20); a cathode(80) opposite to the anode; and an organic layer inserted between the anode and the cathode. The organic layer is one or more layers. The organic layer includes the anthracene derivative. The organic layer includes one or more layers selected from a light emitting layer(50), a hole injection layer(30), a hole transport layer(40), a hole blocking layer, an electron transport layer(60), an electron injection layer(70), and an electron blocking layer.

Synthesis of Bi(hetero)aryls via Sequential Oxidation and Decarboxylation of Benzylamines in a Batch/Fully Automated Continuous Flow Process

Catalytic dehydrogenative cross-coupling of two C–H bonds represents a green strategy in view of the atom- and step-economy. However, the challenge is to discover a new innovative bond strategy, especially for the direct coupling between Csp2–H

ONE STEP DIRECT ARYLATION OF COMMODITY CHEMICALS TO SPECIALTY CHEMICALS BY TANDEM CATALYTIC PLATFORM

The present invention relates to a continuous direct arylation process based on a tandem catalyst for synthesizing specialty chemicals. A method for synthesizing an aryl-aryl structure from a substrate selected from the group consisting of benzyl alcohol, benzyl amine and toluene which are low value added compounds is developed using a silver ion-containing tandem catalyst. The method is applied for synthesizing hexaphenyl arylene and can be applied for synthesizing high value added compounds (not only natural substances and chemical compounds but pharmaceutical and agricultural pesticide relative fields) directly from primary raw materials through the reaction.COPYRIGHT KIPO 2017

Silver-catalyzed arylation of (hetero)arenes by oxidative decarboxylation of aromatic carboxylic acids

A long-standing challenge in Minisci reactions is achieving the arylation of heteroarenes by oxidative decarboxylation of aromatic carboxylic acids. To address this challenge, the silver-catalyzed intermolecular Minisci reaction of aromatic carboxylic acids was developed. With an inexpensive silver salt as a catalyst, this new reaction enables a variety of aromatic carboxylic acids to undergo decarboxylative coupling with electron-deficient arenes or heteroarenes regardless of the position of the substituents on the aromatic carboxylic acid, thus eliminating the need for ortho-substituted aromatic carboxylic acids, which were a limitation of previously reported methods.

ELECTRONIC DEVICE INCLUDING A DIAZACHRYSENE DERIVATIVE

There is provided a compound having Formula I. In Formula I: R1-R10 are the same or different and can be H, D, alkyl, aryl, alkoxy, aryloxy, silyl, or deuterated analogs of alkyl, aryl, alkoxy, aryloxy and silyl, where adjacent R gro

Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity

By use of iterative design aided by predictive models for target affinity, brain permeability, and hERG activity, novel and diverse compounds based on cyclic amidine and guanidine cores were synthesized with the goal of finding BACE-1 inhibitors as a treatment for Alzheimer's disease. Since synthesis feasibility had low priority in the design of the cores, an extensive synthesis effort was needed to make the relevant compounds. Syntheses of these compounds are reported, together with physicochemical properties and structure-activity relationships based on in vitro data. Four crystal structures of diverse amidines binding in the active site are deposited and discussed. Inhibitors of BACE-1 with 3 μM to 32 nM potencies in cells are shown, together with data on in vivo brain exposure levels for four compounds. The results presented show the importance of the core structure for the profile of the final compounds.

SUBSTITUTED IMIDAZOTRIAZINES

This invention relates to novel substituted imidazotriazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases